Evommune

EVMN Lead: Phase 2 3 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-15

Catalyst timeline

EVO756 Ph2b startMid-2026EVO756 Ph2b start, Mid-2026, notable
EVO301 corporate update2H 2026EVO301 corporate update, 2H 2026, routine
EVO756 Ph2b toplineSep 2026EVO756 Ph2b topline, Sep 2026, major
barzolvolimab Celldex Ph3 readout4Q 2026barzolvolimab Celldex Ph3 readout, 4Q 2026, material
EVO756 topline2027EVO756 topline, 2027, major
EVO301 Ph2b startMid-2027EVO301 Ph2b start, Mid-2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (6 active programs)

EVO756

Small Molecule Target: MRGPRX2

Chronic Inducible Urticaria Phase 2 oral NCT06603220
Atopic Dermatitis Phase 2 oral Maruho NCT07150845
Migraine Phase 2 oral Maruho NCT07616128

EVO301

Protein Target: IL-18, IL-18BP

Atopic Dermatitis Phase 2 intravenous AprilBio
Ulcerative Colitis Phase 2 subcutaneous AprilBio
Atopic Dermatitis Phase 2 subcutaneous AprilBio

Discontinued (1)

EVO756 — Chronic Spontaneous Urticaria · trial did not meet primary endpoint; company decided to cease development of EVO756 for CSU

Biotech Distilled coverage (3)

2026-08-07 UPDATE: Evommune (EVMN) - The Clock Moves Up to September 🔒 Paid
2026-06-30 UPDATE: Evommune (EVMN) — The CSU Shot Misses 🔒 Paid
2026-05-22 Evommune (EVMN) — Scientific Deep Dive for EVO756, EVO301 and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.